Miragen therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Miragen therapeutics Contact Number

MiRagen Therapeutics, Inc. Announces Acquisition of

2 hours ago Investors.miragen.com Get All

617.430.7576

Investor Relations contact: Dan Ferry LifeSci Advisors [email protected] 617.430.7576. Media contact: Darby Pearson Verge Scientific Communications [email protected] 703.587.0831 . Source: miRagen Therapeutics, Inc.

Website: http://investors.miragen.com/press-releases/press-release/2020/miRagen-Therapeutics-Inc.-Announces-Acquisition-of-Viridian-Therapeutics-Inc/default.aspx

Category: Contact NumberShow more

Viridian Therapeutics Crunchbase Company Profile & Funding

Just Now Crunchbase.com Get All

303-531-5952

Contact Email [email protected] Phone Number 303-531-5952. Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating

Website: https://www.crunchbase.com/organization/miragen-therapeutics

Category: Contact NumberShow more

MIRAGEN THERAPEUTICS, INC. (Form: 8K, Received: 09/17

3 hours ago Content.edgar-online.com Get All

(617) 430-7576

File Number) (IRS Employer Identification No.) 6200 Lookout Rd. Boulder, CO 80301 (Address of principal executive offices) About miRagen Therapeutics . Investor Relations Contact: Dan Ferry LifeSci Advisors (617) 430-7576. [email protected]

Website: https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-20-248159.html?hash=fa1e610255b5d218234ff2c3a402f6caa64e4893e78997819d2d815215bbbddc&dest=D81875DEX103_HTM

Category: Contact NumberShow more

Bill Perry's email & phone miRagen Therapeutics, Inc.'s

7 hours ago Rocketreach.co Get All

We had no where to begin. Scouring the web at all hours of the night wasn't gonna cut it. RocketReach has given us a great place to start. Our workflow has solid direction now - we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering.

Website: https://rocketreach.co/bill-perry-email_5629414

Category: Phone NumberShow more

MiRagen Therapeutics Company Profile Office Locations

7 hours ago Craft.co Get All

miRagen Therapeutics has 45 employees at their 1 location and $1.05 M in annual revenue in FY 2020. See insights on miRagen Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Employees: 45
Type: Public
Founded: 2007
Website: miragen.com

Website: https://craft.co/miragen-therapeutics

Category: Contact NumberShow more

MiRagen Therapeutics Inc. :: Medtech Insight

Just Now Medtech.pharmaintelligence.informa.com Get All

miRagen Therapeutics Inc. is developing microRNA-based therapeutics for treating cardiovascular and muscle disease. The company is farthest along with researching potential treatments for heart disease. It has advanced several candidates including the miR-15/195 family to improve cardiac remodeling that occurs in heart muscle following a heart attack, miR-208 and miR-499 to address …

Website: https://medtech.pharmaintelligence.informa.com/SC091956/miRagen-Therapeutics-Inc

Category: Tech SupportShow more

Corporate Profile Viridian Therapeutics, Inc.

9 hours ago Investors.miragen.com Get All

Corporate Profile. VRDN $12.22 $ -0.40 (3.17%) Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development

Website: http://investors.miragen.com/corporate-profile/default.aspx

Category: Contact NumberShow more

MiRagen Therapeutics Announces Company Name Change to

1 hours ago Investors.miragen.com Get All

720.643.5200

Viridian Therapeutics 6200 Lookout Rd. Boulder, CO 80301 203 Crescent St., Building 17, Suite 102B Waltham, MA 02453 T: 720.643.5200 F: 720.643.5201 info

Website: http://investors.miragen.com/press-releases/press-release/2021/miRagen-Therapeutics-Announces-Company-Name-Change-to-Viridian-Therapeutics-and-New-Executive-Appointments-Including-Expansion-of-Leadership-Team/default.aspx

Category: Contact NumberShow more

MIRAGEN THERAPEUTICS, INC. (Form: 8K, Received: 07/02

2 hours ago Content.edgar-online.com Get All

Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen’s clinical product candidate for the …

Website: https://content.edgar-online.com/ExternalLink/EDGAR/0001590750-20-000071.html?hash=0e6ccfae25e0e8efe46592dc552d92403caa595017cf59e0b8016c834ee17ef4&dest=A202007028K_HTM

Category: Contact NumberShow more

MiRagen to Host a Key Opinion Leader Call on Idiopathic

1 hours ago Investors.miragen.com Get All

miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call BOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted …

Website: http://investors.miragen.com/press-releases/press-release/2020/miRagen-to-Host-a-Key-Opinion-Leader-Call-on-Idiopathic-Pulmonary-Fibrosis-on-Tuesday-June-23rd/default.aspx

Category: Contact NumberShow more

MiRagen Therapeutics Announces Company Name Change to

1 hours ago Apnews.com Get All

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in …

Website: https://apnews.com/press-release/globenewswire-mobile/business-products-and-services-personnel-product-testing-boulder-85c17d199e2b67b1da2d06402d9d9dba

Category: Contact NumberShow more

MiRagen Strengthens Leadership Team with Appointment of

8 hours ago Investors.miragen.com Get All

BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Ms. Rauch reports directly to President and Chief Executive …

Website: http://investors.miragen.com/press-releases/press-release/2020/miRagen-Strengthens-Leadership-Team-with-Appointment-of-Lee-Rauch-as-Chief-Operating-Officer/default.aspx

Category: Contact NumberShow more

MiRagen Announces First Quarter Viridian Therapeutics

5 hours ago Investors.viridiantherapeutics.com Get All

(720) 407-4595

Investor/Media Contact: Adam Levy, Chief Business Officer (720) 407-4595 [email protected]miragen.com. Miragen Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (unaudited)

Website: https://investors.viridiantherapeutics.com/press-releases/press-release/2019/miRagen-Announces-First-Quarter-2019-Financial-Results--and-Provides-Corporate-Update/default.aspx

Category: Contact NumberShow more

MiRagen Therapeutics and Signal Genetics Sign Merger

5 hours ago Businesswire.com Get All

720-407-4595

miRagen Investor Contact: Adam Levy, 720-407-4595 Chief Business Officer [email protected] or Signal Investor Contact: The Ruth Group David Burke, 646-536-7009 [email protected] Site

Website: https://www.businesswire.com/news/home/20161031006326/en/miRagen-Therapeutics-Signal-Genetics-Sign-Merger-Agreement

Category: Contact NumberShow more

MiRagen reports loss, effects reverse stock split

8 hours ago Dailycamera.com Get All

MiRagen Therapeutics Inc. (Nasdaq: MGEN), a Boulder-based biotechnology company developing new treatments for patients with diseases that are underserved by …

Website: https://www.dailycamera.com/2020/11/12/miragen-reports-loss-effects-reverse-stock-split/

Category: Contact NumberShow more

MiRagen Therapeutics, Inc. Prices Public Offering of

2 hours ago Viridiantherapeutics.com Get All

Company Release – 2/8/2018 6:45 PM ET BOULDER, Colo., Feb. 08, 2018 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common …

Website: https://www.viridiantherapeutics.com/press-release/miragen-therapeutics-inc-prices-public-offering-common-stock/

Category: Contact NumberShow more

Health Care Companies Miragen Therapeutics & Signal

Just Now Pillsburylaw.com Get All

11.04.16

11.04.16. Privately held biopharmaceutical company Miragen Therapeutics Inc. and molecular diagnostic company Signal Genetics Inc. are set to close a deal during the first quarter of next year that will merge the companies under Miragen’s name. The merger will make Miragen a publicly traded company. According to the terms of the deal, Miragen

Website: https://www.pillsburylaw.com/en/news-and-insights/health-care-companies-miragen-therapeutics-and-signal-genetics-set-to-merge.html

Category: Contact NumberShow more

MiRagen Therapeutics, Inc. Announces Acquisition of

7 hours ago Globenewswire.com Get All

On a pro forma basis and based upon the number of shares of miRagen common stock and preferred stock issued in the acquisition and the concurrent financing, miRagen equity …

Website: https://www.globenewswire.com/news-release/2020/10/28/2115807/0/en/miRagen-Therapeutics-Inc-Announces-Acquisition-of-Viridian-Therapeutics-Inc.html

Category: Contact NumberShow more

MIRAGEN THERAPEUTICS, INC. (Form: S8, Received: 11/24

2 hours ago Content.edgar-online.com Get All

We have acted as counsel to Miragen Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the filing of a registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission covering the offering of up to 1,810,948 shares (the “Shares”) of common stock, par value $0

Website: https://content.edgar-online.com/ExternalLink/EDGAR/0001590750-20-000114.html?hash=4c50e0ee7db592b5646f8aa0e10ce0ccde8a5b92e12b1dc1dd82843cc53316ec&dest=A20201124S8EXHIBIT991_HTM

Category: Contact NumberShow more

Miragen Therapeutics Stock Forecast, Price & News (NASDAQ

6 hours ago Marketbeat.com Get All

Miragen Therapeutics, Inc. (NASDAQ:MGEN) issued its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%.

Website: https://www.marketbeat.com/stocks/NASDAQ/MGEN/

Category: Contact NumberShow more

MiRagen Therapeutics, Inc. Announces Acquisition of

7 hours ago Bloomberg.com Get All

On a pro forma basis and based upon the number of shares of miRagen common stock and preferred stock issued in the acquisition and the concurrent financing, miRagen equity …

Website: https://www.bloomberg.com/press-releases/2020-10-28/miragen-therapeutics-inc-announces-acquisition-of-viridian-therapeutics-inc

Category: Contact NumberShow more

MiRagen Therapeutics to Present New Clinical Trial Data

1 hours ago Investors.viridiantherapeutics.com Get All

BOULDER, Colo., May 17, 2017 (GLOBE NEWSWIRE) - Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical study of MRG-106 will be presented on June 5, 2017 at the American Society of …

Website: https://investors.viridiantherapeutics.com/press-releases/press-release/2017/miRagen-Therapeutics-to-Present-New-Clinical-Trial-Data-for-MRG-106-an-Oligonucleotide-Therapeutic-Targeting-microRNA-155-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting/default.aspx

Category: Contact NumberShow more

MiRagen CEO resigns, company hires strategic review adviser

8 hours ago Dailycamera.com Get All

Bill Marshall, a co-founder and former CEO of MiRagen Therapeutics Inc. (Nasdaq: MGEN), has resigned from the Boulder biotech company as it …

Website: https://www.dailycamera.com/2020/09/15/miragen-ceo-resigns-company-hires-strategic-review-adviser/

Category: Contact NumberShow more

MiRagen Therapeutics to Present at the Jefferies 2017

4 hours ago Viridiantherapeutics.com Get All

Company Release – 6/1/2017 7:00 AM ET BOULDER, Colo., June 01, 2017 (GLOBE NEWSWIRE) — Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at …

Website: https://www.viridiantherapeutics.com/press-release/miragen-therapeutics-present-jefferies-2017-global-healthcare-conference/

Category: Contact NumberShow more

MiRagen Therapeutics, Inc. Announces Acquisition of

2 hours ago Finance.yahoo.com Get All

On a pro forma basis and based upon the number of shares of miRagen common stock and preferred stock issued in the acquisition and the concurrent financing, miRagen equity …

Website: https://finance.yahoo.com/news/miragen-therapeutics-inc-announces-acquisition-110000770.html

Category: Contact NumberShow more

MiRagen to Present at the DIA/FDA Viridian Therapeutics

4 hours ago Investors.viridiantherapeutics.com Get All

An overview of its second-generation miR-29 mimics Clinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will present an overview of its novel second generation …

Website: https://investors.viridiantherapeutics.com/press-releases/press-release/2019/miRagen-to-Present-at-the-DIAFDA-Oligonucleotide-Based-Therapeutics-Conference-Today/default.aspx

Category: Contact NumberShow more

MiRagen Therapeutics Inc. (NASDAQ:MGEN) To Halt

9 hours ago Biopharmajournal.com Get All

miRagen Therapeutics Inc. (NASDAQ:MGEN) has announced that it is carrying an internal review of initial topline data from the second phase SOLAR clinical study of cobomarsen in treating Cutaneous T-Cell Lymphoma patients. SOLAR trial of cobaomarsen fails to meet the primary endpoint . Based on investigators’ assessments, the initial data from 37 patients suggests that …

Website: https://biopharmajournal.com/2020/10/15/miragen-therapeutics-inc-nasdaqmgen-to-halt-development-of-cobomarsen-after-solar-study-fails-to-meet-primary-endpoint/

Category: Contact NumberShow more

MiRagen Therapeutics Provides Corporate Update

8 hours ago Marketscreener.com Get All

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and

Website: https://www.marketscreener.com/quote/stock/VIRIDIAN-THERAPEUTICS-IN-34091127/news/miRagen-Therapeutics-Provides-Corporate-Update-24143867/

Category: Contact NumberShow more

MiRagen Therapeutics Reports First Quarter 2017 Financial

3 hours ago Viridiantherapeutics.com Get All

(888) 430-8709

The miRagen Therapeutics management team will host a conference call and webcast today at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2017. The conference call can be accessed by dialing (888) 430-8709 (U.S./Canada) or (719) 457-2714 (international) and providing the passcode 3263108.

Website: https://www.viridiantherapeutics.com/press-release/miragen-therapeutics-reports-first-quarter-2017-financial-results-provides-corporate-update/

Category: Contact NumberShow more

MiRagen to Host a Key Opinion Leader Call on Idiopathic

7 hours ago Finance.yahoo.com Get All

BOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies

Website: https://finance.yahoo.com/news/miragen-host-key-opinion-leader-200110373.html

Category: Contact NumberShow more

MiRagen, Investigators from Goethe University and

9 hours ago Nasdaq.com Get All

About miRagen Therapeutics, Inc. miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on

Website: https://www.nasdaq.com/press-release/miragen-investigators-from-goethe-university-and-university-hospital-frankfurt-and

Category: Contact NumberShow more

MiRagen Regains Compliance With Nasdaq Listing

1 hours ago Globenewswire.com Get All

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a …

Website: https://www.globenewswire.com/news-release/2020/07/02/2057173/0/en/miRagen-Regains-Compliance-With-Nasdaq-Listing-Requirements.html

Category: Contact NumberShow more

MiRagen Therapeutics Announces Board of Director Evolution

1 hours ago Finance.yahoo.com Get All

BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies

Website: https://finance.yahoo.com/news/miragen-therapeutics-announces-board-director-210500426.html

Category: Contact NumberShow more

Current Report Filing (8k) Investors Hub

2 hours ago Ih.advfn.com Get All

On January 4, 2021, Miragen Therapeutics, Inc. (the “Company”) implemented an increase in the number of authorized shares of its Common Stock from 100,000,000 to 200,000,000 pursuant to a Certificate of Amendment to the Company’s Certificate of Incorporation, a copy of which is filed herewith as Exhibit 3.1. Item 5.07.

Website: https://ih.advfn.com/stock-market/NASDAQ/miragen-therapeutics-MGEN/stock-news/84017286/current-report-filing-8-k

Category: Contact NumberShow more

MiRagen Therapeutics, Inc. Announces Acquisition of

9 hours ago Biospace.com Get All

miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. miRagen’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). miRagen is headquartered in Boulder, Colo., with research

Website: https://www.biospace.com/article/releases/miragen-therapeutics-inc-announces-acquisition-of-viridian-therapeutics-inc-/

Category: Contact NumberShow more

MiRagen Announces Internal Review of Preliminary Topline

1 hours ago Finance.yahoo.com Get All

miRagen decides to discontinue further internal development of cobomarsenBOULDER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a …

Website: https://finance.yahoo.com/news/miragen-announces-internal-review-preliminary-200500886.html

Category: Contact NumberShow more

MiRagen Therapeutics Presents New Preclinical Data

Just Now Investors.viridiantherapeutics.com Get All

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen (MRG-106), MRG-201, and MRG-110. miRagen

Website: https://investors.viridiantherapeutics.com/press-releases/press-release/2018/miRagen-Therapeutics-Presents-New-Preclinical-Data-Supporting-use-of-MicroRNA-Targeted-Therapies-for-Ophthalmic-Diseases/default.aspx

Category: Contact NumberShow more

MiRagen Announces Proposed Public Viridian Therapeutics

6 hours ago Investors.viridiantherapeutics.com Get All

BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

Website: https://investors.viridiantherapeutics.com/press-releases/press-release/2020/miRagen-Announces-Proposed-Public-Offering-of-Common-Stock-and-Warrants-to-Purchase-Common-Stock/default.aspx

Category: Contact NumberShow more

An indepth look at the Miragen Therapeutics (MGEN) stock

9 hours ago Marketingsentinel.com Get All

Miragen Therapeutics (NASDAQ:MGEN) has a beta value of 2.31 and has seen 1,055,844 shares traded in the last trading session. The company, currently valued at $61.71 Million, closed the last trade at $1.09 per share which meant it lost -$0.03 on the day or …

Website: https://marketingsentinel.com/2020/08/17/an-in-depth-look-at-the-miragen-therapeutics-mgen-stock-2/

Category: Contact NumberShow more

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

2 hours ago Ih.advfn.com Get All

MGEN Miragen Therapeutics Inc Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) The number of shares that are sold through Jefferies after delivering an issuance notice, if any, will fluctuate based on a number of factors, including the market price of shares of our common stock during the sales period, the limits we set with Jefferies in

Website: https://ih.advfn.com/stock-market/NASDAQ/miragen-therapeutics-MGEN/stock-news/84906327/prospectus-filed-pursuant-to-rule-424b5-424b5

Category: Contact NumberShow more

MiRagen Announces Results of Meeting With FDA Regarding the

8 hours ago Globenewswire.com Get All

Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a …

Website: https://www.globenewswire.com/news-release/2020/08/20/2081663/0/en/miRagen-Announces-Results-of-Meeting-With-FDA-Regarding-the-Design-of-Pivotal-Trial-for-Cobomarsen-in-ATLL.html

Category: Contact NumberShow more

Cobomarsen Receives Orphan Drug Designation From the U.S.

9 hours ago Globenewswire.com Get All

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a …

Website: https://www.globenewswire.com/news-release/2020/07/23/2066961/0/en/Cobomarsen-Receives-Orphan-Drug-Designation-From-the-U-S-FDA-for-the-Treatment-of-T-cell-Lymphoma.html

Category: Contact NumberShow more

MiRagen Announces Encouraging Preclinical Safety and

6 hours ago Nasdaq.com Get All

--miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, …

Website: https://www.nasdaq.com/press-release/miragen-announces-encouraging-preclinical-safety-and-efficacy-data-for-its-next

Category: Contact NumberShow more

Buy, Sell Or Hold Miragen Therapeutics (NASDAQ:MGEN) At $1

8 hours ago Marketingsentinel.com Get All

Miragen Therapeutics’ shares saw a change of 122.96% in year-to-date performance and have moved 3.88% in past 5-day. Miragen Therapeutics (NASDAQ:MGEN) showed a performance of 0.94% in past 30-days. Number of shares sold short was 1.25 Million shares which calculate 0.42 days to cover the short interests.

Website: https://marketingsentinel.com/2020/07/30/buy-sell-or-hold-miragen-therapeutics-nasdaqmgen-at-1-07/

Category: Contact NumberShow more

MiRagen Therapeutics Secures $41 million Series C

2 hours ago Businesswire.com Get All

720-933-0848

miRagen Therapeutics, Inc. News Contact: Kecia Carroll, 720-933-0848 Communications [email protected] or Clinical Trials Contact: Amy Owens, 720-407-4603 [email protected] Release Summary

Website: http://www.businesswire.com/news/home/20151110005530/en/miRagen-Therapeutics-Secures-41-million-Series-Financing

Category: Contact NumberShow more

Miragen Therapeutics 2021 Investment MGEN Macroaxis

7 hours ago Macroaxis.com Get All

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Website: https://www.macroaxis.com/stock/MGEN/Miragen-Therapeutics

Category: Contact NumberShow more

Viridian Therapeutics Funding, Financials, Valuation

9 hours ago Crunchbase.com Get All

Viridian Therapeutics has raised a total of $186.7M in funding over 9 rounds. Their latest funding was raised on Nov 6, 2020 from a Post-IPO Equity round. Viridian Therapeutics is registered under the ticker NASDAQ:MGEN . Their stock opened with $11.73 in its Apr 24, 2017 IPO. Viridian Therapeutics is funded by 11 investors.

Website: https://www.crunchbase.com/organization/miragen-therapeutics/company_financials

Category: Contact NumberShow more

MiRagen Enters into License Agreement with Xencor for use

5 hours ago Finance.yahoo.com Get All

miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. miRagen’s most advanced program, VRDN-001, is a

Website: https://finance.yahoo.com/news/miragen-enters-license-agreement-xencor-120000048.html

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

How to contact miragen therapeutics mgen mailing address?

Miragen Therapeutics is headquartered at 6200 LOOKOUT ROAD, BOULDER CO, 80301. How can I contact Miragen Therapeutics? Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]

Who are the stock holders of miragen therapeutics?

On a pro forma basis and based upon the number of shares of miRagen common stock and preferred stock issued in the acquisition and the concurrent financing, miRagen equity holders immediately prior to the acquisition will own approximately 12% of miRagen on an as-converted basis immediately after these transactions.

Where is the company miragen inclocated?

Historically, these patients have had poor treatment options limited to orbital surgeries, radiation, and steroids. The company is based in Boulder, Colorado, and Waltham, Massachusetts. Loading slideshow...

When do cvrs go out for miragen therapeutics?

In connection with the transactions announced today, a non-transferrable contingent value right (“CVR”) is expected to be distributed to holders of miRagen common stock within the next 30 days.

Brand New Updated

Popular Brands

Merck
Man
Maaden
Mcx
Midea
Metro
Mapfre